Cooper DA - Search Results

1

Effect of therapeutic drug monitoring on outcome in antiretroviral experienced HIV-infected individuals.

Mallon PW, Ray J, Cooper DA. Mallon PW, et al. Among authors: cooper da. J Clin Virol. 2003 Feb;26(2):223-7. doi: 10.1016/s1386-6532(02)00120-8. J Clin Virol. 2003. PMID: 12600653

2

Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy.

Mallon PW, Miller J, Cooper DA, Carr A. Mallon PW, et al. Among authors: cooper da. AIDS. 2003 May 2;17(7):971-9. doi: 10.1097/00002030-200305020-00005. AIDS. 2003. PMID: 12700446

3

Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.

Winston A, Bloch M, Carr A, Amin J, Mallon PW, Ray J, Marriott D, Cooper DA, Emery S. Winston A, et al. Among authors: cooper da. J Antimicrob Chemother. 2005 Aug;56(2):380-7. doi: 10.1093/jac/dki235. Epub 2005 Jul 4. J Antimicrob Chemother. 2005. PMID: 15996972

4

The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.

Winston A, Mallon PW, Satchell C, MacRae K, Williams KM, Schutz M, Law M, Cooper DA, Emery S. Winston A, et al. Among authors: cooper da. Clin Infect Dis. 2007 Jun 1;44(11):1475-83. doi: 10.1086/517507. Epub 2007 Apr 18. Clin Infect Dis. 2007. PMID: 17479946 Clinical Trial.

5

Evolution of CD4+ T cell count in HIV-1-infected adults receiving antiretroviral therapy with sustained long-term virological suppression.

Byakwaga H, Murray JM, Petoumenos K, Kelleher AD, Law MG, Boyd MA, Emery S, Mallon PW, Cooper DA. Byakwaga H, et al. Among authors: cooper da. AIDS Res Hum Retroviruses. 2009 Jun;25(6):756-76. doi: 10.1089/aid.2008.0149. AIDS Res Hum Retroviruses. 2009. PMID: 19500017

6

Rates of transmission of antiretroviral drug resistant strains of HIV-1.

Ammaranond P, Cunningham P, Oelrichs R, Suzuki K, Harris C, Leas L, Grulich A, Cooper DA, Kelleher AD. Ammaranond P, et al. Among authors: cooper da. J Clin Virol. 2003 Feb;26(2):153-61. doi: 10.1016/s1386-6532(02)00114-2. J Clin Virol. 2003. PMID: 12600647 Review.

7

HIV-associated lipodystrophy: description, pathogenesis, and molecular pathways.

Mallon PW, Carr A, Cooper DA. Mallon PW, et al. Among authors: cooper da. Curr Diab Rep. 2002 Apr;2(2):116-24. doi: 10.1007/s11892-002-0070-x. Curr Diab Rep. 2002. PMID: 12643131 Review.

8

Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia.

Mallon PW, Wand H, Law M, Miller J, Cooper DA, Carr A; HIV Lipodystrophy Case Definition Study; Australian Lipodystrophy Prevalence Survey Investigators. Mallon PW, et al. Among authors: cooper da. J Acquir Immune Defic Syndr. 2005 Feb 1;38(2):156-62. doi: 10.1097/01.qai.0000147527.64863.1a. J Acquir Immune Defic Syndr. 2005. PMID: 15671800

9

Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy.

Kovacic JC, Martin A, Carey D, Wand H, Mallon PW, Feneley MP, Emery S, Cooper DA, Carr A; ROSEY Investigators. Kovacic JC, et al. Among authors: cooper da. Antivir Ther. 2005;10(1):135-43. Antivir Ther. 2005. PMID: 15751771 Clinical Trial.

10

Methodological considerations in human studies of gene expression in HIV-associated lipodystrophy.

Mallon PW, Sedwell R, Unemori P, Kelleher A, Cooper DA, Carr A. Mallon PW, et al. Among authors: cooper da. Antivir Ther. 2005;10 Suppl 2:M101-8. Antivir Ther. 2005. PMID: 16152711 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

828 results

Search Page

Filters